Arcturus Therapeutics Holdings Inc. filed a Form 8-K on September 23, 2026, disclosing that it presented an overview of ARCT-810 Phase 2 clinical data and provided an update on its mRNA delivery platform under Regulation FD.

Key Highlights

  • ARCT-810 Phase 2 data presented: Arcturus presented an overview of ARCT-810 Phase 2 clinical data on September 23, 2026.
  • mRNA delivery platform update: The company also provided an update on its mRNA delivery platform as part of the same presentation.
  • Exhibits furnished: A presentation (Exhibit 99.1) and a press release summarizing the presentation (Exhibit 99.2) were furnished with the filing.
  • Regulation FD disclosure: The filing was made under Item 7.01, Regulation FD Disclosure.
  • Signed by CEO: The filing was signed by Joseph E. Payne, Chief Executive Officer of Arcturus Therapeutics Holdings Inc.

Arcturus Discloses ARCT-810 Clinical Update and mRNA Platform Overview

According to the filing, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a Delaware corporation headquartered in San Diego, California, reported on September 23, 2026, that it presented an overview of ARCT-810 Phase 2 clinical data and provided an update on its mRNA delivery platform. The filing describes this as a "Presentation" and notes that the company also issued a press release summarizing the presentation, referred to as the "Release."

The filing discloses that copies of the Presentation and the Release were furnished as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated into Item 7.01 by reference. The 8-K was filed under Regulation FD, which governs the disclosure of material nonpublic information by public companies to the market broadly.

The filing includes the standard notation that the information in Item 7.01, the Presentation, and the Release "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended." The filing was signed on behalf of the registrant by Joseph E. Payne, Chief Executive Officer, on September 23, 2026.

What Was Disclosed

Arcturus Therapeutics filed an 8-K on September 23, 2026, reporting the presentation of ARCT-810 Phase 2 clinical data and an mRNA delivery platform update, with the full presentation and a summarizing press release furnished as exhibits.